Beta
ManageSearchChatDiscover
15369

Insights into Novel Drug Targets in Mycobacterium tuberculosis: Where Do We Stand and Where Do We Go from Here?

Article

Last updated: 22 Jan 2023

OverviewSimilar Items

Subjects

-

Tags

Pharmaceutical chemistry.

Abstract

Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS with 6.3 million new cases of TB reported in 2016. TB is an air-borne disease associated with the aerobic bacterium Mycobacterium tuberculosis (Mtb), which mainly infects the lungs. Aerosolization of diseased pulmonary secretions, by coughing, sneezing and speaking, discharge the Mtb bacilli into the atmosphere. Infected aerosol droplet nuclei sized 1-10 μm are largely trapped in the upper nasal passages or are expelled into the pharynx by the mucociliary mechanism of the lower respiratory tract and are harmlessly swallowed and digested. Infected persons may overcome the initial TB infection, resulting in the development of asymptomatic latent TB. About 10% of individuals may develop the active disease after infection; where the bacteria undergo more rapid growth and overcome the host immune system. In cases of multi-drug resistant (MDR) strains, and extreme drug-resistant (XDR) strains, treatment fails, and the bacteria propagate and attack the host, leading to death from systemic infection. Due to the increased spread of TB worldwide, both the academic and industrial communities have initiated intensive research to develop new therapeutics targeting new enzymes such as cytochrome P450s in Mtb.

DOI

10.21608/rpbs.2018.3874.1004

Keywords

Mycobacterium tuberculosis, Cytochrome P450s, Therapeutics

Authors

First Name

Safaa

Last Name

Kishk

MiddleName

-

Affiliation

a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt b. School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK

Email

safaa_keshk@pharm.suez.edu.eg

City

-

Orcid

-

First Name

Mohamed A.

Last Name

Helal

MiddleName

-

Affiliation

a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt c. Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza 12588, Egypt

Email

mhelal@zewailcity.edu.eg

City

-

Orcid

-

First Name

Mohamed S.

Last Name

Gomaa

MiddleName

-

Affiliation

a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt

Email

mohamed_gomaa@pharm.suez.edu.eg

City

-

Orcid

-

First Name

Ismail

Last Name

Salama

MiddleName

-

Affiliation

a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt

Email

ismail_mohamed@pharm.suez.edu.eg

City

Ismailia

Orcid

-

First Name

Samia

Last Name

Moustafa

MiddleName

-

Affiliation

a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt

Email

samiamostafa2010@hotmail.com

City

Ismailia

Orcid

-

First Name

Claire

Last Name

Simons

MiddleName

-

Affiliation

b. School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK

Email

simonsc@cardiff.ac.uk

City

-

Orcid

-

Volume

2

Article Issue

1

Related Issue

2436

Issue Date

2018-03-01

Receive Date

2018-03-11

Publish Date

2018-09-30

Page Start

14

Page End

21

Print ISSN

2536-9857

Online ISSN

2535-2091

Article File

RPBS_Volume 2_Issue 1_Pages 14-21.pdf

PDF . 757.3kB

Link

https://rpbs.journals.ekb.eg/article_15369.html

Detail API

https://rpbs.journals.ekb.eg/service?article_code=15369

Order

2

Type

Mini-reviews

Type Code

534

Publication Type

Journal

Publication Title

Records of Pharmaceutical and Biomedical Sciences

Publication Link

https://rpbs.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023